NT-proBNP的临床应用进展  

Clinical Application Progress of NT-proBNP

作　　者：陈华[1] 周懿忆[1] 戴屹东 

机构地区：[1]上海交通大学医学院附属瑞金医院卢湾分院放免检验科,上海200020 [2]上海市东南医院检验科,上海200023

出　　处：《标记免疫分析与临床》2015年第1期69-72,共4页Labeled Immunoassays and Clinical Medicine

摘　　要：大量研究表明,NT-proBNP在心力衰竭的诊断以及急性冠脉综合征患者的风险评估中有重要价值,是独立的心血管事件再发生的预后因素,也是独立的心源性死亡发生的危险因素^([1])。另外,NT-proBNP在其它一些疾病中的诊断、预后判断等方面也发挥着重要作用。本文综述了NT-proBNP近年来的临床应用进展。Since Japanese scholar isolated B-type natriuretic peptide（BNP） from pig brain in 1988 and Hunt found N-terminal pro-B-type natriuretic peptide（NT-proBNP） in human plasma in 1995, its application in clinical practice has been developed rapidly. When ventricular volume, pressure load on heart and tension of ventricular muscle increase and myocardial ischemia happens, BNP genes in myocardial cells are activated, generating protein containing 134 amino acid, which becomes natriuretic peptide precursor containing 108 amino acid after signal peptide is removed, rapidly secreted into blood and soon degrading to BNP and NT- proBNP at a ratio of 1： 1. Numerous researches showed that NT-proBNP is of great value in the heart failure and risk assessment of patient with acute recurrence of cardiovascular events and a dangerous diagnosis of coronary syndrome, a prognostic factor of the independent factor of the independent occurrence of cardiac death. In addition, NT-proBNP also plays an important role in other aspects, such as some disease diagnosis and prognosis. Some clinical apolications of NT-oroBNP will be reviewed in this article.

关 键 词：NT-PROBNP 心力衰竭 急性呼吸困难 急性冠脉综合征 房颤 

分 类 号：R446.6[医药卫生—诊断学]